Skip to main content

Table 3 Treatment outcomes

From: Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes

  All patients (n = 30) Castrate-resistant (n = 11) Castrate-sensitive (n = 19) p-value
Biochemical/clinical failure 16 (53%) 10 (91%) 6 (32%) 0.008
Metastatic progression 10 (63%) 7 (64%) 3 (16%) 0.007
Median time to failure, months (range) 16 (6–38) 13 (6–28) 23 (10–38)  
Median RFS, months (range) 22 (6–43) 13 (6–28) 26 (10–43)  < 0.001
2 and 3-year RFS 60% and 53% 18% and 9% 84% and 79%  < 0.001
2 and 3-year MFS   36% and 27% 90% and 90% 0.001
  1. RFS, recurrence-free survival; MFS, metastasis-free survival